TickerGuard
Buy Day today: Good (62) Broad market participation · no major macro event
ADCT

ADC Therapeutics SA

Healthcare · Biotechnology

1.10$ +1.0% vs. previous close Closing price · As of: Sep 17, 2026

Ownership

Ownership Structure

Who owns ADC Therapeutics SA (ADCT)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 69.4% of the shares are freely tradable; institutional investors hold 67.6%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 67.6%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 13.4%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 69.4%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 5.8%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 128Mio.

Largest Shareholders

Institutions

Institutions ADCT
Name Stake (%) Shares Change (%) Date
Redmile Group, LLC 9.03 11,526,710 -25.5 06/30/2026
TCG Crossover Management, LLC 8.92 11,390,175 +0.0 06/30/2026
Prosight Management, LP 6.13 7,824,749 -5.7 06/30/2026
BlackRock Inc 4.90 6,250,747 +15.2 03/31/2026
Nantahala Capital Management, LLC 4.38 5,597,433 +2.2 03/31/2026
Morgan Stanley - Brokerage Accounts 2.99 3,812,582 +1.1 03/31/2026
Point72 Asset Management, L.P. 2.65 3,382,129 -32.6 03/31/2026
Millennium Management LLC 2.27 2,899,535 -7.0 06/30/2026
Citadel Advisors Llc 1.61 2,053,316 +413.7 06/30/2026

Funds

Funds ADCT
Name Stake (%) Shares Change (%) Date
iShares Russell 2000 ETF 2.11 2,695,996 -0.6 08/31/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?